Venus Concept Deferred Revenue 2011-2026 | VERO

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Venus Concept

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
953 K	1.08 M	1.76 M	2.03 M	3.7 M	2.5 M	1.41 M	1.52 M	1.52 M	1.32 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.7 M	953 K	1.78 M

Quarterly Deferred Revenue Venus Concept

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
1.35 M	914 K	880 K	953 K	915 K	894 K	926 K	1.08 M	1.13 M	1.05 M	952 K	1.76 M	1.54 M	1.8 M	1.58 M	2.03 M	420 K	901 K	1.62 M	1.75 M	1.75 M	1.75 M	1.75 M	2.5 M	2.5 M	2.5 M	2.5 M	163 K	1.41 M	1.41 M	1.41 M	1.52 M	1.52 M	1.52 M	1.52 M	1.42 M	1.42 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.5 M	163 K	1.43 M

Deferred Revenue of other stocks in the Medical devices industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
Apollo Endosurgery APEN	88 K	-	-	$ 475 M	USA
GenMark Diagnostics, Inc. GNMK	508 K	-	-	$ 1.77 B	USA
Helius Medical Technologies HSDT	148 K	$ 1.98	-4.81 %	$ 1.2 M	USA
Aziyo Biologics AZYO	533 K	-	1.37 %	$ 20.5 M	USA
AdaptHealth Corp. AHCO	59.8 M	$ 13.09	-2.17 %	$ 1.77 B	USA
Allied Healthcare Products AHPI	563 K	-	3.58 %	$ 2.21 M	USA
BIOLASE BIOL	2.45 M	-	-13.19 %	$ 166 K	USA
BioSig Technologies BSGM	16 K	-	37.08 %	$ 85.7 M	USA
Obalon Therapeutics, Inc. OBLN	424 K	-	-5.86 %	$ 30.6 M	USA
EDAP TMS S.A. EDAP	3.41 M	$ 3.43	3.78 %	$ 128 M	France
Conformis CFMS	215 K	-	-	$ 16.4 M	USA
Insulet Corporation PODD	14 M	$ 178.47	-2.41 %	$ 12.6 B	USA
Cardiovascular Systems CSII	2.11 M	-	0.15 %	$ 844 M	USA
Cytosorbents Corporation CTSO	182 K	$ 0.62	3.3 %	$ 38.6 M	USA
ClearPoint Neuro CLPT	1.67 M	$ 10.53	-4.96 %	$ 298 M	USA
Dynatronics Corporation DYNT	150 K	-	14.99 %	$ 929 K	USA
Sintx Technologies SINT	4.72 K	$ 2.1	-2.33 %	$ 5.82 M	USA
Globus Medical GMED	27.7 M	$ 89.22	-1.68 %	$ 12.1 B	USA
Eargo EAR	621 K	-	-	$ 10.2 M	USA
CryoLife, Inc. CRY	1.45 M	-	-4.14 %	$ 702 M	USA
Second Sight Medical Products EYES	335 K	-	-0.97 %	$ 54.4 M	USA
TransMedics Group TMDX	2.9 M	$ 100.07	-1.18 %	$ 3.4 B	USA
Tandem Diabetes Care TNDM	9.53 M	$ 17.71	-4.94 %	$ 1.2 B	USA
Hancock Jaffe Laboratories, Inc. HJLI	33	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	732 K	-	0.03 %	$ 1.58 B	Israel
Misonix, Inc. MSON	13.3 K	-	-	$ 462 M	USA
Butterfly Network BFLY	16.1 M	$ 4.88	-5.43 %	$ 1.03 B	USA
Intersect ENT, Inc. XENT	137 K	-	-	$ 955 M	USA
Pulmonx Corporation LUNG	18 K	$ 1.23	-	$ 50 M	USA
Varex Imaging Corporation VREX	13 M	$ 11.44	-5.26 %	$ 474 M	USA
Vivos Therapeutics VVOS	500 K	$ 0.82	-3.92 %	$ 8.42 M	USA
Delcath Systems DCTH	170 K	$ 10.35	-1.94 %	$ 371 M	USA
IRIDEX Corporation IRIX	2.16 M	$ 1.04	-	$ 17.6 M	USA
LivaNova PLC LIVN	11.5 M	$ 59.46	-2.99 %	$ 3.24 B	Britain
LENSAR LNSR	2.6 M	$ 5.25	-1.87 %	$ 62.8 M	USA
Integer Holdings Corporation ITGR	5.21 M	$ 84.27	-0.44 %	$ 2.93 B	USA